RESUMEN
BACKGROUND: COVID-19 outbreak was declared as a pandemic by the World Health Organization in March 2020. Over the last 3 months, the pandemic has challenged the diagnosis and treatment of all cancer, including rectal cancer. Constraints in resources call for a change in the treatment strategy without compromising efficacy. RECENT FINDINGS: Delivery of shorter treatment schedules for radiotherapy offers advantages like short overall treatment time, improved throughput on the machine, improved compliance and reduced risk of transmission of COVID 19. Other strategies include delaying surgery, reducing the intensity of chemotherapy and adoption of organ preservation approach. CONCLUSION: The curative treatment of rectal cancer should not be hindered during the COVID pandemic, and modifications in the multi-modality treatment will help achieve quality care.
Asunto(s)
COVID-19/prevención & control , Control de Enfermedades Transmisibles/normas , Pandemias/prevención & control , Oncología por Radiación/organización & administración , Neoplasias del Recto/terapia , COVID-19/epidemiología , COVID-19/transmisión , Quimioradioterapia Adyuvante/métodos , Quimioradioterapia Adyuvante/normas , Humanos , Transmisión de Enfermedad Infecciosa de Paciente a Profesional/prevención & control , Terapia Neoadyuvante/métodos , Terapia Neoadyuvante/normas , Tratamientos Conservadores del Órgano/métodos , Tratamientos Conservadores del Órgano/normas , Equipo de Protección Personal/normas , Oncología por Radiación/métodos , Oncología por Radiación/normas , Radioterapia Adyuvante/métodos , Radioterapia Adyuvante/normas , Neoplasias del Recto/diagnóstico , Telemedicina/métodos , Telemedicina/organización & administración , Telemedicina/normas , Factores de Tiempo , Tiempo de Tratamiento/normas , Resultado del TratamientoRESUMEN
PURPOSE: Today, the rapid outbreak of COVID-19 is the leading health issue. Patients with cancer are at high risk for the development of morbidities of COVID-19. Hence, oncology centers need to provide organ-based recommendations for optimal management of cancer in the COVID-19 era. METHODS: In this article, we have provided the recommendations on management of locally advanced rectal cancer during the COVID-19 pandemic based on our experience in Shohada-e Tajrish Hospital, Iran. RESULTS: We recommend that patients with locally advanced rectal cancer should be managed in an individualized manner in combination with local conditions related to COVID-19. CONCLUSION: Our recommendation may provide a guide for oncology centers of developing countries for better management of locally advanced rectal cancer.
Asunto(s)
Betacoronavirus/patogenicidad , Infecciones por Coronavirus/prevención & control , Oncología Médica/normas , Pandemias/prevención & control , Neumonía Viral/prevención & control , Guías de Práctica Clínica como Asunto/normas , Neoplasias del Recto/terapia , Factores de Edad , Anciano , Anciano de 80 o más Años , Protocolos de Quimioterapia Combinada Antineoplásica/normas , Protocolos de Quimioterapia Combinada Antineoplásica/uso terapéutico , Betacoronavirus/aislamiento & purificación , COVID-19 , Quimioterapia Adyuvante/normas , Toma de Decisiones Clínicas , Consenso , Infecciones por Coronavirus/epidemiología , Infecciones por Coronavirus/transmisión , Infecciones por Coronavirus/virología , Humanos , Control de Infecciones/normas , Irán/epidemiología , Oncología Médica/métodos , Terapia Neoadyuvante/normas , Estadificación de Neoplasias , Cuidados Paliativos/métodos , Cuidados Paliativos/normas , Selección de Paciente , Neumonía Viral/epidemiología , Neumonía Viral/transmisión , Neumonía Viral/virología , Proctectomía/normas , Neoplasias del Recto/patología , Recto/patología , Recto/cirugía , SARS-CoV-2RESUMEN
The objective of this document is to formalize a degraded mode management for patients with thoracic cancers in the context of the COVID-19 pandemic. The proposals are based on those of the French High Council for Public Health, on published data outside the context of COVID-19, and on a concerted analysis of the risk-benefit ratio for our patients by a panel of experts specialized on thoracic oncology under the aegis of the French-Language Society of Pulmonology (SPLF)/French-language oncology group. These proposals are evolving (10 April 2020) according to the situations encountered, which will enrich it, and are to be adapted to our institutional organisations and to the evolution of resources during the COVID-19 epidemic. Patients with symptoms and/or COVID-19+ are not discussed in this document and are managed within the framework of specific channels.